Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Sotorasib/BBP-398 Combo Snags FDA Fast Track Status for KRAS G12C–Mutated NSCLC

October 12th 2022

A combination regimen comprised of sotorasib and BBP-398 has been awarded a fast track designation from the FDA for use as a potential therapeutic option in adult patients with previously treated, KRAS G12C–mutated, metastatic non–small cell lung cancer.

Avelumab and Axitinib Elicits Responses in Advanced Thymoma and Thymic Carcinoma

October 12th 2022

The combination of avelumab and axitinib demonstrated promising response rates and progression-free survival and an expected safety profile in pretreated patients with advanced type B3 thymoma and thymic carcinoma, according to findings from an ongoing phase 2 study.

Enhancing Communication Among the Multidisciplinary Care Team

October 12th 2022

Bhuvana Ramkumar, MD, and Neil Morganstein, MD, share standards of communication among the care team at their clinical practice sites.

Challenges With and Strategies for Tissue Procurement in NSCLC

October 12th 2022

Drs Benjamin Levy, Neil Morganstein, and Bhuvana Ramkumar discuss challenges of procuring for molecular testing in patients with NSCLC.

Expert Puts the Accent on Curative Potential in NSCLC Landscape

October 12th 2022

Mark A. Socinski, MD, has become internationally known for his research into the molecular drivers of lung cancer and his contributions to the refinement of multidisciplinary care.

Major Adverse Events of Anti-HER2 Therapies

October 10th 2022

Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.

HER2-Targeted Therapies in NSCLC

October 10th 2022

Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.

Investigators Seek to Resolve the “Obesity Paradox” in Lung Cancer

October 10th 2022

Smoking is associated with the most widely known cancer causing carcinogen across the world. However, a second, more insidious factor has been increasingly recognized for its role in promoting cancer growth: obesity.

Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC

October 7th 2022

Drs Vamsidhar Velcheti and Solange Peters discuss the optimum length for immunotherapy treatment in resectable NSCLC, highlighting the issue of payer authorizations.

Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

October 7th 2022

Oncologists explain data from the NADIM II and AEGAN clinical trials investigating treatments for neoadjuvant immunotherapy in resectable NSCLC.

Durvalumab, Tremelimumab, and Chemotherapy Elicit Promising Long-Term OS Rates in NSCLC

October 6th 2022

Melissa L. Johnson, MD, expands on the updated data from the POSEIDEN trial, the rationale for investigating the combination, and what these results mean for the treatment of metastatic non–small cell lung cancer.

Dostarlimab Plus Chemotherapy Meets ORR End Point in Metastatic Nonsquamous NSCLC

October 5th 2022

The addition of dostarlimab to chemotherapy led to an improvement in objective response rate vs pembrolizumab plus chemotherapy in patients with newly diagnosed metastatic nonsquamous non–small cell lung cancer.

Molecular Testing in Early NSCLC to Guide Treatment Decision Making

October 5th 2022

Jonathan Spicer, MD, explains the role of molecular testing in patients with stage I-IIIA NSCLC, and how it informs treatment decision-making.

Recommendations for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC)

October 5th 2022

A panel of lung cancer experts provides an overview of molecular testing in early-stage non-small cell lung cancer (NSCLC) and recommendations for biomarkers to test for and at what treatment stages to perform testing.

FDA Awards Fast Track Designation to Eftilagimod Alpha Plus Pembrolizumab in Frontline NSCLC

October 5th 2022

The FDA has granted a fast track designation to eftilagimod alpha for use in combination with pembrolizumab as a frontline treatment for patients with stage IIIB/IV non–small cell lung cancer.

Dr. Johnson on the Evolution of Frontline Treatment in NSCLC

October 5th 2022

Melissa L. Johnson, MD, discusses the evolution of frontline treatment in non–small cell lung cancer.

Sapanisertib Gets FDA Fast Track Status for Pretreated NRF2-Mutated Squamous NSCLC

October 4th 2022

The FDA has granted a fast track designation to sapanisertib as a potential therapeutic option in patients with unresected or metastatic squamous non–small cell lung cancer whose tumors harbor an NRF2 mutation and who have previously received platinum-based chemotherapy and immune checkpoint inhibition.

Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC

October 4th 2022

Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.

Current Treatment Options in NSCLC

October 4th 2022

Dr Mark A Socinski reviews the currently available treatment options for NSCLC, including targeted therapies.

Testing Patients with NSCLC for HER2 Mutations

September 29th 2022

Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.